Skip to main content
OpenTrials
Completed

NCT Number: NCT03355846

Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments

Starting from the observation that acute anal fissure (AAF) in 6-8 weeks can heal spontaneously and that some of the commonly used commercial products in clinical practice would seem to be useful, the rationale of the comparative study is to try to identify, in compliance with the protocol of Helsinki (2013), the most effective short-term treatment for the disappearance of pain in defecation and cessation of bleeding, shortening the duration of the healing process and favoring the patient's rapid return to his / her activity, respect for patient safety.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of General Surgery "Paride Stefanini", University of Rome "La Sapienza"

Rome, RM, 00161, Italy

About this study

Starting from the observation that anal fissure in 6-8 weeks can heal spontaneously and that some of the commonly used commercial products in clinical practice would seem to be useful, the rationale of the comparative study is to try to identify, in compliance with the protocol of Helsinki (2013), the most effective short-term treatment for the disappearance of pain in defecation and cessation of bleeding, shortening the duration of the healing process and favoring the patient's rapid return to his / her activity, respect for patient safety.

The comparative study will be conducted by comparing the following products:

  • Centella® Complex 1 cps 60 mg per os after meals twice a day for 15 days;
  • Proctocella® Complex cream to be applied in anal area and anal canal after hygiene treatment for 4 weeks;
  • Flavonil® 1 cps 300 mg per os after meals twice a day for 15 days;
  • Flavonil® Cream Cream to be applied in anal region and anal canal after hygiene treatment for 4 weeks;
  • Rectalgan Mousse cleansing cleanser for anal and perineal region for 4 weeks.

Our approach attempts to blend, based on the evidence of the most recent scientific literature, the experience of decades of colonproctologic clinical practice that has a predominantly surgical approach, with the clinical evidence of the Science of Nutrition which has a conservative vision in the treatment of ailments and constipation, a predisposing factor in the pathogenesis of anal fissure, in order to obtain healing without surgery. The control group will receive the traditional basic treatment consisting in the application of lubricated anal dilators of increasing gauge according to predetermined pattern, hygiene and diet. The two groups with which they will be compared for the results will receive, in addition to the foregoing (for controls), or Flavonoids (ProtFlav) or Asian Centella Extract (ProtCent), in the form of local mouth and cream tablets to be applied at the perianal level and possibly in the anal canal with gloved finger, containing the same active principles also administered by mouth.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects With Acute Anal Fissure
  • Collaborative patients able to understand and want;

Exclusion criteria

  • Pregnancy

Treatment and study plan

Centella

Drug

after meals twice a day for 15 days

Proctocella

Drug

after hygiene treatment for 4 weeks;

Flavonil® cps

Drug

after meals twice a day for 15 days

Flavonil® Cream

Drug

treatment for 4 weeks;

.

Rectalgan Mousse

Drug

for 4 weeks

Primary outcomes

  1. time for the disappearance of pain

    Time frame: 1 month

    time for the disappearance of pain in course of treatment

Secondary outcomes

  1. time for the disappearance of bleeding

    Time frame: 1 month

    time for the disappearance of bleeding in course of treatment

Sponsors and collaborators

Lead sponsor

University of Roma La Sapienza

Other

Registry information

Acronym: PBSAAF

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Nov 28, 2017
Registry last updated
Jul 13, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.